No Data
No Data
Junshi Bio (01877.HK): Toripalimab has been approved for listing in China Hong Kong.
On October 15th, Junshi Bio (01877.HK) announced that its wholly-owned subsidiary, Topalliance Biosciences Hong Kong Limited, recently obtained the 'Drug/Product Registration Certificate' issued by the Pharmacy and Poisons Board (PPB) in Hong Kong. The certificate approves a combination of Toripalimab (commodity name in Hong Kong: LOQTORZI) with cisplatin/gemcitabine as first-line treatment for adult patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma, as well as monotherapy.
Express News | Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR
junshi bio (688180.SH): Toripalimab monoclonal antibody approved for listing in Hong Kong, the first and only immunotherapy drug for nasopharyngeal carcinoma tumors.
junshi bio (688180.SH) announced that its wholly-owned subsidiary, Topallai Biomedical Hong Kong Limited...
Shanghai Junshi Biosciences' Cholesterol Drug Gets NDA From NMPA; Shares Down 5%
junshi bio (688180.SH): The new drug application for Angoriximab injection was approved.
JUNSHI BIO (688180.SH) announced on October 11th that the company learned from the website of the National Medical Products Administration that the NMPA approved the company's application for the commercialization of Angoriximab injection (recombinant humanized anti-PCSK9 monoclonal antibody injection, trade name: JUNSHIDA) for the treatment of primary hypercholesterolemia (non-familial) and diversified bond lipid abnormalities in adults. This is the company's fifth approved commercial product. Indications: In addition to dietary control, in combination with statins, or in combination with statins and ezetimibe, for use in moderate to moderate dose.
[Brokerage Focus] China Post Securities expects the pharmaceutical sector to continue to rise uniformly, suggesting prioritizing the layout of various segmented sectors and leading companies in the first and second tiers during the general rise phase.
Golden Herald Financial News | China Post Securities stated that since the end of September, the pharmaceutical sector has been boosted by the national comprehensive incremental policy, solidly promoting the economy towards a higher-quality structure under the heavy bullish push, leading to a rapid rebound of the index by about 29%, reversing the continuous decline of nearly 4 years. Looking at the current PE (TTM), A-share pharmaceuticals are at 32 times, and Hong Kong stocks at 23 times. The previous continuous decline has already deviated from the fundamentals. The bank believes that the increase in market risk appetite will accelerate the sector's valuation repair. As of H1 2024, the institutions hold a 7.3% stake in the CSI SWS Health Care Index sector, which, although slightly lower than the end of 2023, still remains at a historically high level, indicating a general positive sentiment among institutions.
No Data
No Data